Jurnal Internasional
Jurnal Internasional
Jurnal Internasional
*Acharya Vidhi M.
ABSTRACT
Article Received on
01 March 2018, The simple, specific, accurate & precise RP-HPLC method have been
Revised on 22 March 2018,
developed and validated for simultaneous estimation of triple dose
Accepted on 12 April 2018
DOI: 10.20959/wjpr20189-11944 combination which is used to treat hypertension. The triple
combination is of Hydrochlorothiazide, Amlodipine besylate and
*Corresponding Author Irbesartan. In this method the chromatographic system was equipped
Acharya Vidhi M. with Phenomenax C18 column (25cm x 0.46 cm, 5µ) as stationary
“Gurukrupa” 4, SVP road B/H phase and UV detector set at 224 nm, in conjunction with a mobile
Balahanuman Temple
phase of Phosphate Buffer(pH 4.5): Acetonitrile in theration of 55:45%
Surendranagar-363001
Gujarat, India.
v/v ratio at a flow rate of 1.0ml/min. the retention time of
Hydrochlorothiazide was 3.489 min, for Amlodipine besylate it was
4.181 min & the retention time of Irbesartan was 11.376 min. This method was linear with
correlation coefficient 0.9970, 0.9974 & 0.9973 respectively. Also there was no any
interference of diluent with chromatogram of standard & sample. The % recovery were
99.37, 100.70 & 100.28%. Also it was statistically validated for accuracy, precision,
specificity & robustness as per ICH guidelines. After analyzing the data of validation, we can
say that this method can be used for further analysis. As this proposed method is rapid,
specific, accurate, and robust with good resolution & short run time. So, the method can be
used for routine analysis.
INTRODUCTION
Chemically Hydrochlorothiazide is 6-chloro-1, 1-dioxo-3, 4-dihydro-2H-1λ⁶, 2, 4-
Literature review reveals different analytical methods for this triple dose combination. These
methods include UV-Visible spectrophotometry, LC, HPLC, HPTLC, GC, Potentiometric
titration, LC-MS fir estimation of either single drug or in combination with other drugs but
there is no any RP-HPLC method for simultaneous estimation for this stated combination.
Therefore, attempt was made to develop and validate simple, precise, accurate, specific and
robust RP- HPLC method for estimation of simultaneous estimation of these three drug in
their combined dosage form as a tablet. The method was developed and validated as per ICH
guideline Q2 (R1).
METHOD DEVELOPMENT
Selection of Wavelength
Suitable wavelength for the HPLC analysis was determined by recording UV spectrums in
the range 200-400 nm. Here solution of 25µg/ml Hydrochlorothiazide, 13.92µg/ml
Amlodipine besylate and 300µg/ml Irbesartan was prepared in methanol and measured.
Suitable wavelength selected for the estimation of this combined drug is 224nm.
Chromatographic Condition
Table 1 chromatographic condition
Stationary phase C18 (25cm x 0.46 cm, 5µm) Phenomenax
Mobile phase Phosphate Buffer (pH 4.5) : Acetonitrile (55:455v/v)
Detection Wavelength 224 nm
Injection volume 10 μl
Flow rate 1.0 ml/min
Column Temperature 25°C
Run time 15 minutes
Concentration Of API in Irbesartan :- 300 µg/ml Amlodipine Besylate :- 13.92
standard solution µg/ml
(throughout all trials) & Hydrochlorothiazide :- 25 µg/ml
a) Preparation of Diluent
3.40 gm Potassium dihydrogen ortho phosphate (KH2PO4) was weighed and dissolved in
1000 ml Water. Adjusted pH 6.00 ± 0.05 with Diluted NaOH solution and filtered with 0.45µ
membrane filter. Mix thoroughly 400 volume of Phosphate Buffer and 600 volume of
Acetonitrile as diluent.
volumetric flask, add 20 ml of diluent, mix and make up the volume with diluent.
METHOD VALIDATION
Validation of the developed RP-HPLC method was carried out as per ICH guidelines Q2
(R1).
1) Specificity
Specificity of method can be termed as absence of any interference at retention times of
samples. Specificity was performed by injecting blank and standard preparations.
Chromatograms were recorded and retention times from sample and standard preparations
were compared for identification of analytes.
3) Precision
The method was validated in terms of intra-day inter-day precision. The solution containing
12.5, 25 & 37.5 µg/ml Hydrochlorothiazide, 6.69, 13.92 & 20.88 µg/ml Amlodipine besylate
and 150, 300& 450 µg/ml Irbesartan were injected for inter-day and intra-day study.
Repeatability study was performed by injecting standard sample solutions six times.
4) Accuracy
Accuracy was determined by calculating recovery of drugs by placebo method. Known
amounts of standard solutions of Hydrochlorothiazide (20, 25 & 30 μg/ml), Amlodipine
besylate (11.15, 13.92, and 16.70 μg/ml) and Irbesartan (240, 300 and 360μg/mL) were added
to a pre quantified placebo test solutions of Hydrochlorothiazide, Amlodipine besylate and
Irbesartan. Each solution was injected in triplicate and the recovery was calculated by
measuring peak areas.
5) Robustness
The robustness study was performed to evaluate the influence of small but deliberate
variation in the chromatographic condition. The robustness was checked by making three
small changes in chromatographic parameters. The mobile phase ratio was changed by ±2 ml,
the wavelength was changed by ±2 nm and the flow rate was changed by ±0.02 ml/min. After
each changes sample solution was injected and system suitability parameters were observed.
Composition giving retention time of 3.489 min for Hydrochlorothiazide, 4.181 min for
Amlodipine besylate and 11.376 min for Irbesartan with good resolution and theoretical
plates was selected, that optimized mobile phase was Buffer: ACN (55:45% v/v pH 3.40 with
OPA). SST parameters were within the accepted limits and was ideal for the injected sample.
A chromatogram of the mixture in optimized conditions is shown Figure 3 and the system
suitability parameters are shown in Table3.
Method validation
1. Linearity
Linearity is ability of method to provide results directly proportional to the concentration of
analyte. The calibration data of Hydrochlorothiazide, Amlodipine besylate and Irbesartan is
given in Table 3.
2. Precision
Repeatability was studied by calculating %RSD for six replicate injections on same day
under same experimental conditions. The obtained %RSD value for Hydrochlorothiazide was
0.05%, 0.824% for Amlodipine besylate and 0.098% for Irbesartan. It was found to be <2%,
which indicate repeatability of proposed method.
Interday precision study reveals % RSD 0.71-1.07 for Hydrochlorothiazide, 0.27-0.47 for
Amlodipine besylate and 0.30-0.69 for Irbesartan respectively. While the % RSD for intraday
was 0.12-1.70 for Hydrochlorothiazide, 0.59-1.01 for Amlodipine besylate & 0.10-0.57 for
Irbesartan. Which is also <2%. So, the method is precise and reproducible. Data for all there
three parameters are given in Table 6.
3. Accuracy
It is estimated by placebo method for three replicates of three different solution containing
80% 100% and 120% of target concentration. The obtained recovery of 80%, 100% & 120%
range for Hydrochlorothiazide were 101.46, 99.37 & 101.46; for Amlodipine besylate they
were 101.64, 100.70 & 100.81 while for Irbesartan they were 101.75, 100.28 & 100.16
respectively. The values of recovery reveal accuracy of method.
Table 7 Recovery data for HCTZ & AMLO AND IRBE by Placebo method
Amount Total Amount
Accurac
Drug Added found* % Recovery ± SD
y Level
(µg/ml) (µg/ml)
HCTZ 80% 20.00 20.33 101.46±0.287
100% 25.00 24.78 99.37±0.268
120% 30.00 29.71 101.46±0.287
AMLO 80% 11.15 11.17 101.64±0.252
100% 13.92 14.01 100.70±0.780
120% 16.70 16.82 100.81±0.165
IRBE 80% 240.00 241.81 100.75±0.124
100% 300.00 300.12 100.28±0.310
120% 360.00 360.23 100.16±0.150
*= average of six determination
4. Robustness
The result and range of three different variables selected for robustness testing are given in
Table 6. The values indicate no significance changes in chromatographic pattern when small
deliberate modifications were made in the experimental conditions, thus the developed
method to be robust.
Summary of all the parameters including RSD values are given following.
Table 9 Result of Validation Parameter
Parameter Result
Sr. No.
DRUG HCTZ AMLO IRBE
1. Specificity Specific
y= y= y=
Regression
266774.6429x 276063.2143x 8623393.5714x
2. Linearity equation
+ 680.7857 – 684.9286 – 56855.0000
R2 0.9970 0.9974 0.9973
Accuracy 80% 101.46 101.64 100.75
3. (% 100% 99.37 100.70 100.28
recovery) 120% 101.46 100.81 100.16
Repeatability 0.05 1.82 0.098
Precision
4. Interday 0.71-1.07 0.27-0.47 0.30-0.69
(%RSD)
Intraday 0.12-1.70 0.59-1.01 0.10-0.57
%RSD for all the parameter were
5. Robustness found well within acceptance criteria.
So, the method was found to be robust.
CONCLUSION
All the parameters and results were found within the accepted limits. So it could be
concluded that the developed RP-HPLC method for simultaneous estimation of combined
dosage form of Hydrochlorothiazide, Amlodipine besylate and Irbesartan was simple,
selective, precise, linear, accurate, robust and sensitive. Thus the method can be applied for
routine quality control sample testing.
ACKNOWLEDGEMENT
I’m grateful to Dr. Ankit B. Chaudhary for providing his support and knowledge throughout
my research work.
REFERENCES
1. Tripathi KD. Essential of Medical Pharmacology; 5th edition; New Delhi: Jaypee
Brothers Medical Publishers, 2008; 424- 433.
2. Irbesartan”, September 2017, https://medlineplus.gov/druginfo/meds/a698009.html
3. “Amlodipine Besylate”, September 2017,
https://medlineplus.gov/druginfo/meds/a692044.html.
4. “Hydrochlorothiazide: Pharmacology and Biochemistry”, September 2017,
https://pubchem.ncbi.nlm.nih.gov/compound/hydrochlorothiazide.
5. Ramesh GC, Stephen W, Sinny D, “Hypertension: Pathophysiology and Treatment” j of
neurology & neurophysiology, 2014; 5(6): 1-8.